Revathy Krishnamurthy

Revathy Krishnamurthy

Auto-generated profile, based on publicly available information

Revathy Krishnamurthy

Tata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Mumbai, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in JCO Global Oncology
Verified
Journal Article
Open access
RKRevathy Krishnamurthy
Revathy Krishnamurthy
NMNaveen Mummudi
Naveen Mummudi
JGJayant Sastri Goda
Jayant Sastri Goda
SCSupriya Chopra
Supriya Chopra
BHBen Heijmen
Ben Heijmen
JSJamema Swamidas
Jamema Swamidas
The radiotherapy (RT) process from planning to treatment delivery is a multistep, complex operation involving numerous levels of human-machine interaction and requiring high precision. These steps are labor-intensive and time-consuming and require meticulous coordination between professionals with diverse expertise. We reviewed and summarized the current status and prospects of artificial intelligence and machine learning relevant to the various steps in RT treatment planning and delivery workflow specifically in low- and middle-income countries (LMICs). We also searched the PubMed database using the search terms (Artificial Intelligence OR Machine Learning OR Deep Learning OR Automation OR knowledge-based planning AND Radiotherapy) AND (list of Low- and Middle-Income Countries as defined by the World Bank at the time of writing this review). The search yielded a total of 90 results, of which results with first authors from the LMICs were chosen. The reference lists of retrieved articles were also reviewed to search for more studies. No language restrictions were imposed. A total of 20 research items with unique study objectives conducted with the aim of enhancing RT processes were examined in detail. Artificial intelligence and machine learning can improve the overall efficiency of RT processes by reducing human intervention, aiding decision making, and efficiently executing lengthy, repetitive tasks. This improvement could permit the radiation oncologist to redistribute resources and focus on responsibilities such as patient counseling, education, and research, especially in resource-constrained LMICs.

1 September 2020 in Brachytherapy
Verified
Journal Article
Closed access
RKRevathy Krishnamurthy
Revathy Krishnamurthy
TWTabassum Wadasadawala
Tabassum Wadasadawala
PRPallavi Rane
Pallavi Rane
RPReena Phurailatpam
Reena Phurailatpam
RSRajiv Sarin
Rajiv Sarin

28 March 2022 in Journal of Radiotherapy in Practice
Verified
Journal Article
Closed access
PDF file
GSGarima Shrivastav
Garima Shrivastav
DDDebanjali Datta
Debanjali Datta
TWTabassum Wadasadawala
Tabassum Wadasadawala
PRPallavi Rane
Pallavi Rane
SPSubhajit Panda
Subhajit Panda
RSRajiv Sarin
Rajiv Sarin
Aim: To evaluate efficacy of helical tomotherapy (HT) for treatment of breast cancer with internal mammary lymph node involvement. Methods: This is a retrospective clinical audit of planning, dosimetry, toxicity and short-term survival of a cohort of 65 patients. Patients were treated between November 2014 and May 2019. The primary and nodal region was prescribed a dose of 50 Gray (Gy) in 25 fractions, while all cases of breast conserving surgery received a simultaneous integrated boost to a dose of 61 Gy in 25 fractions. Results: The 95% coverage for the primary, supraclavicular, internal mammary node and tumour bed was 93·4%, 96·8%, 90·7% and 98·3%, respectively. Mean dose to total lung, heart and contra-lateral breast was 10·6 Gy, 6·92 Gy and 4·32 Gy, respectively. None developed grade III skin or oesophageal toxicity. Twenty-one patients had progression; of which eighteen developed only distant failure while three also had loco-regional recurrence. At a median follow-up of 36 months, the 3-year loco-regional control, disease-free survival and overall survival were 93·5, 73·9 and 85·9%, respectively. Conclusion: We report encouraging clinical outcome for patients treated uniformly with HT. The predominant pattern of failure was distant metastases which suggests the need for systemic control intensification.

1 April 2026 in Indian Journal of Cancer
Verified
Journal Article
Open access
AMAnuradha Mehta
Anuradha Mehta
DSDebdeep Samaddar
Debdeep Samaddar
PBPrabhat Bhargava
Prabhat Bhargava
ASAnbarasan Sekar
Anbarasan Sekar
GJGeorge John
George John
SRSushmita Rath
Sushmita Rath
Background: Hormone receptor-positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC) is associated with a persistent risk of recurrence despite optimal local therapy and adjuvant endocrine therapy, particularly in patients with high-risk clinicopathologic features. Adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant benefits in randomized clinical trials; however, real-world data from Indian populations remain limited. This study evaluates real-world outcomes, tolerability, and treatment adherence to adjuvant CDK4/6 inhibitors in HR+/HER2 − EBC patients treated at a tertiary cancer center in India. Methods: This single-center, retrospective observational study included consecutive adult patients with HR+/HER2 − EBC who received adjuvant endocrine therapy in combination with either ribociclib or abemaciclib following definitive surgery between January 2023 and December 2025. Demographic, clinicopathologic, treatment, toxicity, and outcome data were extracted from institutional medical records. Adverse events were graded using common terminology criteria for adverse events. The primary endpoints were treatment tolerability and invasive disease-free survival (iDFS). Secondary endpoints included overall survival, dose modifications, and treatment discontinuation rates. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 75 patients (median age: 52 years) were analyzed. Stage III disease was present in 69.3% of patients, including IIIA/IIIB/IIIC, and ≥4 positive lymph nodes were observed in 70.6%, representing a high-risk group. Node-negative status was seen in 10 (13.3%) patients. Ribociclib was administered to 55.3% of patients and abemaciclib to 43.4% of patients, and dose modifications were required in 14.2% and 18.1% of patients, respectively, while permanent discontinuation occurred in 3.6% of ribociclib-treated patients and none in the abemaciclib group. Grade ≥3 toxicities were infrequent. In the ribociclib group, grade 3–4 neutropenia occurred in 6.0%, anemia in 4.7%, thrombocytopenia in 2.3%, and diarrhea in 2.3% of patients. In the abemaciclib group, grade 3–4 neutropenia was observed in 6.0%, anemia in 3.0%, thrombocytopenia in 3.0%, and diarrhea in 12.1%, the latter being the most frequent severe adverse event. At a median follow-up of 6.35 months, iDFS was 100% at 6 months and 90.6% at 12 months. Conclusion: In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 − EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies.

17 June 2026 in European Journal of Breast Health
Verified
Journal Article
Open access
PDF file
MJMeenu Jose
Meenu Jose
SSShivani Sable
Shivani Sable
TWTabassum Wadasadawala
Tabassum Wadasadawala
RSRajiv Sarin
Rajiv Sarin
RPRima Pathak
Rima Pathak
MMMayur Mantri
Mayur Mantri
Safety and Early Outcomes of Immediate Autologous Breast Reconstruction in Advanced Breast Cancer: An Indian Experience - European Journal of Breast Health